XENE
Xenon Pharmaceuticals Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 9 to Mar 13 ▼ 3 days of insider sells: $10.6M by 3 insiders, avg $59.52
- Mar 13 ▼ Three executive insiders at Xenon Pharmaceuticals (XENE) sold shares…
- Apr 19 ▲ Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 and long-te…
- May 7 Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/sh…
- Jun 5 ▼ 2 insiders sell $133.5K at $53.14
- Jun 30 ▲ 3 funds open new positions (13F)
- Aug 11 ▼ 1 insider sell $640.6K at $64.06
- Aug 28 ▼ 1 insider sell $425.8K at $60.25
- Sep 18 ▼ Deutsche Bank downgrades
- Sep 30 ▲ 2 insiders buy $1.7M at $37.36
- Oct 1 ▲ Xenon Pharmaceuticals' CEO and CFO made open-market purchases totali…
- Nov 9 ▲ Earnings: XENE Q3 2026 Earnings: EPS $-1.11 (+4.0% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders bought $1.7M at an average $37.36. 6 insiders sold $11.8M. Price is 5% above their cost.
- InstitutionsBULLISH
Q2 2026: 37 added (3 new), 20 trimmed or exited. Largest new: Marshall Wace $41.6M, Panagora Asset Management $40.1M.
- AnalystsBULLISH
23 of 25 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$1.194 → −$1.145 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +0.2% to 7.36M shares. 6.4 days to cover, ≈7.6% of shares.
- TrendRANGE
4% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $454.1M |
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | $196.1M |
| JPMORGAN CHASE & CO | ADD | $157.4M |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | $86.0M |
| CITADEL ADVISORS LLC | TRIM | $84.6M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $82.7M |
| Pictet Asset Management Holding SA | ADD | $71.6M |
| Nuveen, LLC | DOUBLED | $59.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
25 analystsPrice is below the lowest target. Median implies +82%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 18, 2026 | RBC Capital MAINTAIN | Outperform |
| Sep 18, 2026 | Wedbush MAINTAIN | Outperform |
| Sep 18, 2026 | Wells Fargo MAINTAIN | Overweight |
| Sep 18, 2026 | Deutsche Bank DOWNGRADE | Hold |
| Sep 18, 2026 | Needham MAINTAIN | Buy |
| Sep 18, 2026 | Baird MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kelly Thomas Patrick Chief Financial Officer Oct 15, 2026 | EXERCISE | 7,500 sh |
MORTIMER IAN PRESIDENT & CEO Sep 30, 2026 | BUY | $1.1M |
Kelly Thomas Patrick Chief Financial Officer Sep 30, 2026 | BUY | $559.7K |
Svoronos Dawn Director Sep 1, 2026 | EXERCISE | $41.9K |
KENNEY CHRISTOPHER JOHN Chief Medical Officer Aug 28, 2026 | SELL | $383.1K |
KENNEY CHRISTOPHER JOHN Chief Medical Officer Aug 28, 2026 | SELL | $42.7K |
GANNON STEVEN Director Aug 11, 2026 | SELL | $640.6K |
Cannon Gillian Director Jun 5, 2026 | SELL | $63.2K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.14 | -$1.29–-$0.94 | +0.5% | $416.7K |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 3 press releases · 1 bullish · 3 bearish · 1 mixed · 11 neutral- NEUTRAL SC 13GNov 16, 2026
Polar Capital Holdings Plc filed a Schedule 13G disclosing a 5.19% passive stake in Xenon Pharmaceuticals as of September 30, 2026, representing 5,022,084 shares. This is a new passive position by a UK-based asset manager, adding to the existing institutional ownership by T. Rowe Price (10.3%) and…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 9, 2026
Xenon reported Q3 2026 results with a net loss of $110.4M, wider than the $90.9M loss in Q3 2025…
The December 2026 X-NOVA2 MDD topline data readout is the next major catalyst; positive results could de-risk the psychiatry pipeline and offset concerns from the voluntary enrollment pause. Monitor…
- NEUTRAL SC 13G/ANov 6, 2026
T. Rowe Price Investment Management filed an amended Schedule 13G reporting a 10.3% passive stake…
Monitor for any further stake changes or conversion to a 13D filing, though T. Rowe Price's passive certification makes activist intent unlikely. The increase is consistent with normal portfolio…
- NEUTRAL SC 13GNov 6, 2026
T. Rowe Price Investment Management filed a Schedule 13G disclosing a 8.2% passive stake in Xenon…
T. Rowe Price's 8.2% passive stake adds a major institutional holder to the base. Monitor future 13G amendments for any stake changes and watch for any 13D conversion if the holder's intent shifts…
All XENE filing & press-release reports (19)
- SC 13G reportNov 16, 2026
- 8-K reportNov 9, 2026
- SC 13G/A reportNov 6, 2026
- SC 13G reportNov 6, 2026
- SC 13G/A reportNov 5, 2026
- PRESS-RELEASE reportNov 3, 2026
- INST-CLUSTER reportNov 3, 2026
- CLUSTER reportOct 1, 2026
- PRESS-RELEASE reportJul 2, 2026
- 144 reportJun 5, 2026
- 8-K reportJun 3, 2026
- PRESS-RELEASE reportMay 7, 2026
- DEFA14A reportApr 22, 2026
- PRESS-RELEASE reportApr 19, 2026
- PRESS-RELEASE reportApr 15, 2026
- 8-K reportApr 13, 2026
- PRESS-RELEASE reportApr 7, 2026
- CLUSTER reportMar 13, 2026
- PRESS-RELEASE reportMar 12, 2026